Rawzan Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.75 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
About Rawzan Pharma
Rawzan Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 March 2018 (Six years and ten months 23 days old ). Its registered office is in Patna, Bihar, India.
The Corporate was formerly known as Mech Pharma Private Limited. The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M, as per Ministry of Corporate Affairs (MCA) records.
Syed Ahmad, Syed Ahmad, and Syed Ajmal serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U51100BR2018PTC037429
- Company No.
037429
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Rawzan Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Syed Ahmad  | Director | 09-Mar-2018 | Current |
| Syed Ahmad | Director | 09-Mar-2018 | Current |
| Syed Ajmal | Director | 09-Mar-2018 | Current |
Financial Performance of Rawzan Pharma.
Enhance accessibility to Rawzan Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rawzan Pharma?
Unlock access to Rawzan Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Vomanto Private LimitedSyed Ahmad is a mutual person
Northsky Constructions Private LimitedSyed Ahmad and Syed Ajmal are mutual person
- Alhambra Developers Private Limited
Syed Ahmad and Syed Ajmal are mutual person
- Sky Pain Free Physio And Healthcare Private Limited
Syed Ahmad is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rawzan Pharma?
Unlock and access historical data on people associated with Rawzan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rawzan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rawzan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
